Adjuvant and neoadjuvant therapies in melanoma

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.

Gastric Carcinoma Neoadjuvant and Adjuvant Therapy

1.1 Epidemiology In the last 80 years, the incidence of gastric cancer and gastric cancer-related mortality has decreased significantly. However, gastric cancer is the 4th most common cancer and the 2nd common cause of cancer associated mortality in the world (Crew, K.D. Neugut, A.I., 2006, Ferlay, J., et al., 2010, Ferlay, J., et al., 2010, Jemal, A., et al., 2010, Krejs, G.J., 2010, Malvezzi,...

Neoadjuvant and Adjuvant Chemotherapy of Cervical Cancer.

Neoadjuvant chemotherapy is indicated in patients who can tolerate the side effects of a chemotherapy and with preoperative presentation of one of the following clinical risk situations: bulky disease with a maximal tumor diameter of > 4 cm, suspicious lymph nodes in magnetic resonance imaging (MRI), computed tomography (CT) scan or endosonography, histopathologically confirmed lymph node metas...

Neoadjuvant therapy for locally advanced melanoma: new strategies with targeted therapies

Neoadjuvant chemotherapy has been successfully tested in several bulky solid tumors, but it has not been utilized in advanced cutaneous melanoma, primarily because effective medical treatments for this disease have been lacking. However, with the development of new immunotherapies (monoclonal antibodies specific for cytotoxic T lymphocyte-associated antigen 4 [anti-CTLA-4] and programmed death ...

Adjuvant Therapy: Melanoma

With an incidence that is increasing at 2-5% per year, cutaneous melanoma is an international scourge that disproportionately targets young individuals. Despite much research, the treatment of advanced disease is still quite challenging. Immunotherapy with high-dose interferon-α2b or interleukin-2 benefits a select group of patients in the adjuvant and metastatic settings, respectively, with si...